TPO and autoimmune thrombocytopenic purpura: At present, TPO receptor agonists (TPO-RAs), such as eltrombopag and romiplostim, have shown remarkable efficacy in increasing platelet counts in patients with chronic/persistent ITP [12,13,14,15] and are thereby widely adopted as second-line treatment around the world.